Answers are grounded in this paper and cite their sources.
Medical suitability of organ donors is generally determined by evaluation of patient age, medical and social history, organ-specific function, and serologic testing for infectious disease. Given the impact of donor-transmitted infections upon the outcome of organ transplantation, detection of infection using serologic screening is an important measure of donor suitability. Although donor screening for human immunodeficiency virus type 1 (HIV*), human T-lymphotrophic virus (HTLV) type I, hepatitis B, hepatitis C, and cytomegalovirus is routinely performed in the United States (Table 1)(1), there are no worldwide standards (2). The practices among organ procurement organizations (OPOs) vary widely, as do the interpretation and the reporting of the results (3). This review will summarize current knowledge about serologic donor screening for solid organ transplantation and discuss the utility of screening for organ donor suitability as well as the impact of latent donor infections upon recipient outcome. HIV INFECTION HIV has been transmitted from infected cadaver donors to multiple recipients of organs, resulting in the death of the allograft recipients(4). United Network for Organ Sharing (UNOS) policy states that organs from donors with a positive antibody screening to HIV are not suitable, unless subsequent confirmation testing indicates that the screening test was falsely positive. However, a confirmatory Western blot test cannot usually be performed emergently before the maximum time of cadaver organ preservation elapses. Therefore, for all practical purposes, a cadaver donor serum testing positive for HIV by the preliminary enzyme-linked immunosorbent assay results in the discard of all donor organs for transplantation. In contrast, there is ample time to perform confirmatory testing upon living donors. All living organ donors should undergo voluntary screening for HIV, within 2-3 months before the planned transplant. During that interval, donors should be instructed to avoid societal encounters that might endanger an HIV exposure. For example, HIV has been transmitted from an asymptomatic living donor of a renal allograft (whose serology was HIV-negative 8 months before the transplant) following homosexual activity between the time of the HIV testing and the transplant (5). The American Red Cross is now screening blood and tissue donors for HIV p24 antigen (the core structural protein of the virus) by a Food and Drug Administration licensed method (6). This new test may be available for organ donor screening in the future. It enables HIV antigen detection within 30 days of exposure, in a window period when a patient may have viremia prior to the development of antibodies (7). The estimated average time between the p24 detection and the development of HIV antibody is approximately 7 days; thus, its temporal value may be limited. However, the importance of p24 antigen detection is underscored when the rare situation arises in which the organ donor is negative for HIV antibody by serology. Simonds et al. has reported the transmission of HIV to seven recipients of organs and tissues from a seronegative donor, who had HIV p24 antigen retrospectively identified in cultured spleen tissue(8). Presumably, p24 antigen would have been detected in a current peripheral blood sample. Five of the seven recipients (including the heart, liver, and kidney recipients) died with HIV infection. Because of the risk of HIV transmission to blood, tissue, and organ transplant recipients, the Centers for Disease Control (CDC) has developed guidelines for prevention of spreading HIV to organ and tissue recipients(Table 2)(9). The OPO staff should obtain a social history on all potential organ donors that addresses these criteria. When the social history of the potential donor reveals any of the CDC criteria, the risk of HIV transmission (despite negative serology screening) must be balanced against the benefit contemplated for a particular allograft recipient. Thus, organs may be recovered without restriction either for recipients with life-threatening illnesses (heart and liver) or for recipients of non-lifesaving transplants (lung, pancreas, kidney, bowel). In either circumstance, however, the CDC guidelines emphasize a requirement for the transplant center to inform recipients of the potential risk of donor HIV infection, even if that risk is presented only by the behavioral social history (10). Potential donors with a history of incarceration in a correctional institution should be assessed by the usual standards; however, a negative serology for HIV and hepatitis may be sufficient to permit unrestricted donation, if 6 consecutive months have elapsed since incarceration. Nevertheless, given the hazard of previous intravenous drug use in this population, some inmates may not be suitable donors because of positive serology screening. HTLV I INFECTION Although UNOS policy regarding HTLV I screening is the same as it is for HIV (organ donors are not suitable), not all OPOs reject a cadaver donor whose serology screening test reveals a positive anti-HTLV I(3). The risk of transmission of HTLV I by solid organ transplantation has not been clearly defined. HTLV has been transmitted to recipients of contaminated blood transfusions (11). However, depending upon the emergent nature and life-threatened status of a particular candidate for transplantation (especially heart or liver), a patient may have little alternative but to accept an organ from a donor whose screening for HTLV I is positive. There is also a possibility that the screening test is falsely positive. The social history may be helpful in discerning whether there is a likelihood of a true-positive result being subsequently determined by confirmatory testing. A patient infected with HTLV I by blood transfusion is at risk for the development of either adult T-cell leukemia or neurologic disorders(12). Thus, HTLV I is considered hazardous, and consistent with UNOS policy, many regard a positive donor screening for HTLV I to be an absolute contraindication to organ donation. HEPATITIS B INFECTION There are a several serologic profiles for potential organ donors who have been infected with hepatitis B. Furthermore, the implications of donor infectivity vary according to both the serologic profile and the organ to be donated. The following review is categorized by the possible hepatitis B results reported by an OPO to the transplant center. HEPATITIS B SURFACE ANTIGEN (HBsAg)-POSITIVE HBsAg may be identified in the serum of an infected patient within 30-60 days of exposure. Hepatitis B virus (HBV) transmission has been documented to occur through organ transplantation (13, 14). Thus, detection of HBsAg in the donor blood sample indicates the donor is at risk for transmitting HBV. However, the OPO should verify the quality of the serum sample, as a false-positive result can arise from a hemolyzed sample of donor blood. Liver allografts from HBsAg-positive donors have been transplanted successfully to critically ill HBsAg-negative recipients in life-threatened clinical situations (15). Renal allografts transplanted from HBsAg-positive donors to HBsAg-negative recipients have also been performed without the development of HBV infection in the recipient; however, the satisfactory clinical course may have been influenced by the presence of previous immunization to HBV (16). Transplant physicians should recognize that there is a potential for a poor outcome when organs are transplanted from HBsAg-positive donors (deaths from HBV infection) even to HBsAg-positive recipients. When the HBsAg-positive result is verified by repeat testing of donor blood, organ procurement would likely be considered for heart recipients in a life-threatening emergency status, especially those candidates who are anti-HBs-positive (by virtue of immunization or natural immunity). ISOLATED ANTI-HBs-POSITIVE (HBsAg-NEGATIVE AND ANTI-HBc-NEGATIVE) This serologic profile of a donor blood sample could be observed after the vaccination of an individual with hepatitis B vaccine, after the administration of hepatitis B immune globulin (HBIG), after the transfusion of a blood product from an immunized donor, or after previous HBV infection. Antibody to HBsAg, unlike antibody to the HBV core antigen (anti-HBc), does not arise during the acute infection but rather during convalescence. Thus, up to 6 months may elapse before anti-HBs may be detected following HBV infection. However, anti-HBc is usually detectable soon after exposure to the HBV, and it will usually persist (see below: the now well accepted importance of detecting anti-HBc). The donor with isolated anti-HBs is not likely to transmit HBV infection because there is no evidence of active viral replication. However, HBV DNA has been detected by the use of polymerase chain reaction (PCR) in the sera and liver of patients with idiopathic chronic liver disease, whose sera were HBsAg-negative and anti-HBs-positive (17). Moreover, the Mayo Clinic and University of California, San Francisco groups, in a joint report, have observed that a cadaver donor with a serology profile of HBsAg-negative, anti-HBs-positive, and anti-HBc-negative has transmitted HBV to a liver allograft recipient (18). They concluded that the sera from such donors may harbor HBV (as detected by PCR DNA analysis) despite the negative HBsAg. We should also note, however, that this circumstance seems to be rare (<1%). Therefore, a donor serology profile of isolated anti-HBs-positive does not seem to be a contraindication by itself to the recovery of all organs from such a donor, especially if the medical history of the donor reveals hepatitis B vaccination or the administration of HBIG. However, if no such medical history is determined, there is a rare possibility of HBV transmission from a cadaver donor to a liver allograft recipient with this serologic profile (18). ANTI-HBs-POSITIVE, ANTI-HBc-POSITIVE (HBsAg-NEGATIVE) Anti-HBc (IgM) is the earliest antibody detected following HBV infection(10-14 days). Anti-HBc (IgG) can persist for the lifetime of a previously infected patient. Although it has been generally accepted that a serologic profile of HBsAg-negative, anti-HBs-positive, and anti-HBc-positive reveals recovery and immunity to HBV infection, HBV may still reside in the donor patient's liver. Recent literature reports have emphasized the importance of anti-HBc detection regardless of the anti-HBs result(19, 20). Although the presence of the anti-HBs may suggest donor immunity to HBV, the detection of anti-HBs does not necessarily reduce the hazard of HBV transmission from donors who are anti-HBc-positive, especially among liver allograft recipients (21). It is now well established that HBV has been transmitted to liver allograft recipients from cadaver donors whose blood sample revealed a serologic profile of anti-HBc-positive and anti-HBs-positive (negative HBsAg)(22-25). The liver continues to harbor HBV (J. Hoofnagle, M.D., National Institutes of Health, Bethesda, MD, personal communication, 1997), and following transplantation, HBV can replicate in the newly immunosuppressed environment. Dr. Hoofnagle and his colleagues have reviewed the Pittsburgh database of organ donors to determine the consequences of transplanting a liver allograft from an anti-HBc-positive donor to an HBsAg-negative recipient(19). There were 23 isolated anti-HBc-positive, HBsAg-negative donors from 982 HBsAg-negative donors. Some of these donors were anti-HBs-positive. During a mean follow-up of 3.2 years, 19/23 (83%) developed hepatitis B (none of the recipients was HBV+ prior to transplantation). Therefore, although donor anti-HBs-positive status may be associated with donor immunity to HBV, it does not necessarily protect the liver transplant recipient from transmission. Douglas et al. have recently reviewed the long-term experience with de novo HBV infection transmitted from an organ donor and have suggested that the clinical course may be relatively mild (26). It also seems that the risk of HBV transmission from isolated anti-HBc-positive donors is predominantly for the liver allograft recipient. This serologic profile may not carry the same risks for the recipients of extra-liver organs(20). In the University of California, San Francisco review, only 1 of 42 kidney and 0 of 7 heart allograft recipients became HBsAg-positive following transplantation of organs from isolated anti-HBc-positive donors, whereas 3 of 6 liver recipients became HBsAg-positive after transplantation from anti-HBc-positive donors. Mount Sinai Medical Center and the New York Regional Transplant Program have also recently analyzed the outcome of 52 HBsAg-negative recipients of allografts from 21 anti-HBc-positive donors. Although 4 of 16 liver allograft recipients became HBsAg-positive, none of the kidney nor heart recipient serologies became positive (27). ISOLATED ANTI-HBc-POSITIVE (HBsAg-NEGATIVE AND ANTI-HBs-NEGATIVE) A profile of isolated anti-HBc positivity may reflect the window of time in which anti-HBs has yet to be serologically detectable in an HBV-infected individual. An insufficient period has elapsed for the anti-HBs to become positive. Anti-HBc may be the only marker indicating current HBV infection, as the HBsAg has decreased in the peripheral blood to levels that are no longer detectable, and the anti-HBs has yet to increase in sufficient titer as to be detectable. The anti-HBc determination is not influenced by exposure to HBV vaccine. This serology profile is a potential concern for all allograft recipients. HBsAg-negative anti-HBcAb-positive donors can transmit HBV to renal allograft recipients, as noted recently by Satterthwaite et al.; thus, anti-HBc-positive donors must be considered cautiously (28). Miller and associates have proposed testing donor kidney tissue and serum for PCR analysis on HBsAg-negative anti-HBcAb-positive donors, further clarifying the risk of HBV transmission for renal allograft recipients(29). Donor liver functions are routinely performed to determine organ suitability, but these may be abnormal because of hemodynamic consequences. Therefore, a pretransplant liver biopsy should be performed on all anti-HBc-positive donors to examine for portal piecemeal necrosis consistent with active hepatitis (20). If the biopsy is positive for hepatitis, a true-positive anti-HBc is likely, and the risk of HBV transmission is high. Finally, there is an association of anti-HBc-positive donors with a serology positive for hepatitis C virus (HCV). A review of the serologic profiles of nearly 1000 New England Organ Bank donors has revealed 44 donors who had isolated anti-HBc, and 10 of 44 had concomitant HCV. Thus, the detection of HCV raises the suspicion that the anti-HBc-positive result is a true positive. We should also note that a false-positive anti-HBc result (by the enzyme-linked immunosorbent assay method) may occur because of testing methodology in as many as 30% of the positive results (R. Dodd, Ph.D., American Red Cross, Rockville, MD, personal communication, 1997). Moreover, Turner has assessed the prevalence of anti-HBc positivity by screening the sera of HBsAg-negative organ donors. of the sera in which anti-HBc was detected as positive by the assay were as anti-HBc-positive with subsequent testing by Therefore, false-positive of this the for to true could either a positive anti-HBs or HCV serology a liver biopsy or the PCR analysis of donor kidney tissue Some OPOs do not assay for anti-HBs in the serologic of a donor M.D., Mount Sinai personal communication, and only on the anti-HBc If the HBsAg is negative and the anti-HBc is there are no to organ If the serologic donor profile reveals HBsAg-negative, anti-HBc-positive, the anti-HBc-positive result is further by testing for donor organs would not likely be recovered because the result indicates HBV exposure. However, donor organs may be recovered for life-threatened HBsAg-negative recipients or recipients who are In either of the Dr. Miller his recipients with following transplantation Nevertheless, it is that the determination of an anti-HBs result may be in whether organs should be transplanted from a donor with a serology profile of HBsAg-negative and Although the detection of a positive anti-HBs that an anti-HBc-positive result is likely to be a true the positive anti-HBs determination may that the risk of HBV transmission to recipients is has recently upon the implications of detecting an anti-HBc-positive serology in an organ donor was in HBV infection from an anti-HBc-positive donor for a patient who a transplant because of HBV infection. has also been successfully to patients with de novo HBV infection following transplantation Finally, the presence of anti-HBs in the potential allograft following the previous administration of HBV may also be an important The risk of HBV infection by transplantation of a liver allograft from a donor who is anti-HBc-positive is for recipients who have anti-HBs (J. M.D., University of personal communication, 1997). 3 a of the risks to the transmission of HBV infection by results of the donor serology testing and regarding suitability for transplantation. HEPATITIS C The hazard of HCV transmission from a previously infected organ donor is a concern for all allograft recipients. of all organ donors are The presence of antibody is of an HCV infection, as antibody in a peripheral blood sample within months of HCV exposure. OPOs have a policy of screening organ donors for all organ donors should be for antibody using a that has and with The antibody to HCV does not of donor organ however, it is also important to emphasize that detecting in the donor serology is not of HCV transmission of patients have detectable hepatitis C viremia by PCR analysis of a peripheral blood All organ donors will transmit HCV to allograft recipients however, the risk of HCV transmission from a donor is the use of PCR testing chain DNA cannot be within the time of the preservation period for the of the donor Thus, of all organ donors would the possibility of HCV however, such an policy would discard some organs that are not infected with The of an organ from a donor who is is as approximately of the recipients have detectable have detectable hepatitis C viremia by the PCR and may liver However, the risk of transmission of HCV to allograft recipients a positive screening result does not necessarily organ an heart allograft when the is is an accepted even the recipient is a restriction of transplanting organs from an donor has been Because the of HCV infection in an immunosuppressed allograft recipient is usually not many regard a positive donor serology for HCV as a contraindication to transplantation. et al. have suggested a of organs from donors for recipients with a previous HCV exposure and detectable There is evidence in both and human that with donor can occur in recipients this is not without However, liver transplantation from an donor to an recipient does not seem to an or Furthermore, the from an donor could also be for those who are or and may have a for a transplant or a relatively This seems to be as the long-term risk of chronic hepatitis in renal transplant recipients has now been well documented The of et al. established the organ donor as a important of infection in the organ recipient. Thus, all organ donors and recipients should be routinely for antibody to The presence of antibody in either the donor or the recipient indicates the presence of latent viral infection. The donor and recipient serologic status has implications for the risk being recipients of donor organs the infection of an organ from a donor results in subsequent of the latent virus and of the immunosuppressed In there is evidence that from the donor can occur in recipients However, evidence that donor can be successfully by at several in kidney, liver, and transplantation decreased among recipients of Centers transplantation have to donors from recipients because of and The development of has been associated with and associated with as well as infection is associated with an risk of organ allograft and Nevertheless, from many of these in the of infection or The for serologic testing of donors and have been developed for blood donor screening as a are and generally may patients or donors as falsely positive. It is personal experience that false-positive results may occur in about of donors. However, from a prevention this may be because would not to a positive donor as The transplantation of donor organs has not been considered an absolute contraindication to transplantation despite the risks This is especially for potential living organ donors The for such organs to be transplanted has been the of the virus in the The prevalence among both organ donors and recipients from to depending on age, status, and of with in and the development of has the outcome for patients organs from donors. a practical donor testing for should be performed before any blood or product transfusion to an organ This clearly the risk of transmission from the organ of organ donors after blood transfusion an of the risk of transmission in the blood given to the donor, even this risk would be risk of an organ donor from blood product Furthermore, testing after donor transfusion also the possibility of a false-positive organ donor result because of antibody transmitted in the blood of antibody in to antibody has been by some However, it is experience that is not in the of Furthermore, the assay it is not as as the that are available and false-positive results are not Therefore, from a practical would not use as there is no by screening for antibody to ANTIGEN The detection of antibody to by the test is not a contraindication to organ procurement but it is a contraindication to tissue The is in of patients with but it may be negative between 6 and months after infection. Although can be transmitted by blood transfusion are of a infection of a transplant recipient from a Moreover, a course of would sufficient to in an allograft recipient This has been in the of renal allograft recipients given from an organ donor whose serology for were positive Thus, a recipient of any organ donor should be for days with for those who are or The possible transmission of the is a concern especially for heart allograft recipients because of the of this for tissue Organ procurement from donors is not however, the detection of that the recipient may be at the use of transmission of The transmission of such as and have been reported from tissue Thus, organ donor associated with these donation. Although transplantation of renal allografts from donors with and liver has been reported some transplant may be to recipient to an of donor of potential adult donors are for thus, screening of organ donors for has not been routinely However, infection, transplantation of an organ from an donor to an is associated with an risk of disease. Therefore, of this in a potential allograft recipient to be may have important there is no of this AND an organ at the time of a patient's death the risk of transmitting infectious by donor organs contaminated with However, OPOs now routinely donor infection on an individual the blood the presence and of and the nature of the donor infection, before a patient as an organ The risk of may be influenced by an to or a current or However, none of these organ donation. with may also be for organ donation. and are the The administration of at a to a potential donor is these However, carry a hazard for blood following transplantation. For and infections such as and have been transmitted to allograft recipients from infected donors or infected preservation and in the of recipient and of allograft In the of if a sufficient course of has been that the risk of organ may be considered recovery may still be when the donor has a In contrast, is because the for donor is limited. Because infections are to the transplant many transplant B through the the donor during the recovery When serology screening reveals a positive confirmatory testing may be subsequently performed by for The of the New England Organ Bank is to the positive to the who for donation, if there is a hazard that the donor might have transmitted infection to that with This that any would be who is at risk of exposure to HBsAg, HIV, or such would not to or who to donation.
No takes yet. Share an insight, caveat, or question.
Delmonico et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: